Barclays Maintains Advaxis to Overweight with Price Target $20.00

Brokerage firm Barclays Maintains its rating on Advaxis(NASDAQ:ADXS). In a research note issued to the investors, the brokerage major Raises the price-target to $20.00 per share. The shares have been rated Overweight. The rating by Barclays was issued on Aug 3, 2016.

Advaxis (ADXS) made into the market gainers list on Fridays trading session with the shares advancing 0.21% or 0.03 points. Due to strong positive momentum, the stock ended at $14.18, which is also near the day’s high of $14.8. The stock began the session at $14.2 and the volume stood at 10,26,836 shares. The 52-week high of the shares is $22.2 and the 52 week low is $5.21. The company has a current market capitalization of $487 M and it has 3,43,46,687 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On May 13, 2016, Thomas J Mckearn (director) sold 4,100 shares at $7.45 per share price.Also, On May 2, 2016, Robert Petit (Chief Scientific Officer) sold 2,785 shares at $7.51 per share price.On May 2, 2016, Daniel O’connor (Chief Executive Officer) sold 8,237 shares at $7.51 per share price, according to the Form-4 filing with the securities and exchange commission.

Advaxis Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the body’s natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy axalimogene filolisbac (ADXS-HPV) targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer Phase I/II in head and neck cancer and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *